Intelligence · Clinical Pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
- Programs
- 5,568
Quick answer
Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 401 programs
- United Therapeutics Europe 219 programs
- George Institute for 174 programs
- Takeda 163 programs
- AstraZeneca 145 programs
- HOFFMANN-LA ROCHE 145 programs
- MSD Merck Sharp 131 programs
- Anaxis Pharma 129 programs
- Regeneron UK 128 programs
- Telethon Foundation 113 programs
- Novartis India 112 programs
-
PEMBROLIZUMAB, PEMETREXED DISODIUM, CISPLATIN, PEMETREXED DISODIUM, Relatlimab + Nivolumab Fixed Dose Combination (FDC), CARBOPLATIN
Bristol-Myers Squibb Australia Pty Ltd
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
1 trial -
PEMETREXED , GEMCITABINE , PACLITAXEL , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion.
Partner Therapeutics Limited
Stage IIB-IIIB (N2) resectable non small cell lung cancer
1 trial -
PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN , PACLITAXEL , pembrolizumab, CISPLATIN
Merck Sharp and Dohme
Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
1 trial -
PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN
Pari Pharma GmbH
Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)
1 trial -
PEMETREXED, PALONOSETRON, Adagrasib, PEMBROLIZUMAB, CARBOPLATIN, tablets, CISPLATIN
Bristol-Myers Squibb Australia Pty Ltd
Locally Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
PEMETREXED, VINORELBINE, Rilvegostomig, MYCOPHENOLATE MOFETIL, ETOPOSIDE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, Datopotamab deruxtecan
AstraZeneca AB
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature
1 trial -
PF-02341066
Pfizer
Carcinoma, Non-Small-Cell Lung
2 trials -
PF-05280014
Pfizer
Metastatic Breast Cancer
1 trial -
PF-05280586
Pfizer
Follicular Lymphoma
1 trial -
PF-06801591
Pfizer
Non-muscle Invasive Bladder Cancer
1 trial -
PF-06821497, Tablet to match Placebo for PF-06821497 250mg, PF-06821497, ENZALUTAMIDE, Tablet to match Placebo for PF-06821497 125mg
Pfizer Australia Pty Ltd
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
1 trial -
PIRTOBRUTINIB, IBRUTINIB, PIRTOBRUTINIB, IBRUTINIB
Wuhan Createrna Science and Technology Co., Ltd
Mantle cell lymphoma
1 trial -
PIRTOBRUTINIB, IDELALISIB, RITUXIMAB, BENDAMUSTINE HYDROCHLORIDE, PIRTOBRUTINIB, IDELALISIB
Wuhan Createrna Science and Technology Co., Ltd
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
PIRTOBRUTINIB, RITUXIMAB, PIRTOBRUTINIB, BENDAMUSTINE
Wuhan Createrna Science and Technology Co., Ltd
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
PONATINIB, PONATINIB, Ponatinib, IMATINIB, IMATINIB
Takeda
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1 trial -
PREDNISOLONE , PREDNISONE , -, Ifinatamab Deruxtecan, PARACETAMOL , -, DOCETAXEL , -, -, -
Merck Sharp and Dohme
Metastatic Castration-Resistant Prostate Cancer
1 trial -
PREDNISOLONE , Verzenios 50 mg film-coated tablets, Placebo to match LY2835219 (Abemaciclib) Tablets, Placebo to match LY2835219 (Abemaciclib) Capsules, PREDNISONE , ABIRATERONE
Eli Lilly Co.
Prostate Cancer
1 trial -
PREDNISONE, BMS-986365, ENZALUTAMIDE, ABIRATERONE, DOCETAXEL, PREDNISOLONE, ABIRATERONE, ENZALUTAMIDE
Celgene Europe Limited
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1 trial -
PREDNISONE, DOXORUBICIN , BENDAMUSTINE , VINCRISTINE , VINCRISTINE, CYCLOPHOSPHAMIDE , OBINUTUZUMAB, RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, BENDAMUSTINE, RITUXIMAB, PREDNISONE , RITUXIMAB, OBINUTUZUMAB
Fondazione Telethon ETS
Follicular Lymphoma
1 trial -
PSMA-11 kit for Ga-68 labelling
Bial Portela & Companhia S.A.
Intermediate and high-risk prostate cancer
1 trial -
PV-10 (10% rose bengal disodium)
PROVECTUS BIOPHARMACEUTICALS, INC.
Cutaneous Melanoma
1 trial -
Paclitaxel
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Paclitaxel
Cellectar Biosciences
Non Small Cell Lung Cancer
1 trial -
Paclitaxel 6 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion
Gilead Sciences Pty Limited
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1 trial -
Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Armisarte 25 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion.
Lacuna Pharma Pty Ltd
Non-small Cell Lung Cancer
1 trial -
Paclitaxel 6mg/ml Concentrate for Solution for Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Tamoxifen 20 mg Tablets, Epirubicin 2 mg/ml Solution for Injection, Endoxana Injection 500 mg Powder for Solution for Injection, Anastrozole 1 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion
Ningbo Cancer Hospital
Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less
1 trial -
Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, Albotiva 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bendatax 6 mg/ ml, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung
Incyte
Metastatic nonsquamous or squamous non-small cell lung cancer
1 trial -
Paclitaxel Aurobindo 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ipilimumab, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBOPLATIN, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, TAXOL 6 mg/ml, concentrato per soluzione per infusione., OPDIVO 10 mg/mL concentrate for solution for infusion., Paclitaxel-GRY® 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CISPL
Bristol-Myers Squibb Australia Pty Ltd
Stage IV Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Summit Therapeutics
Metastatic Squamous Non-small Cell Lung Cancer
1 trial -
Paclitaxel dosing according to SmPC
BRIGHT MINDS BIOSCIENCES INC.
Carcinoma, Non-Small-Cell Lung
1 trial -
Paclitaxel or docetaxel + Cisplatin or carboplatin
The First People's Hospital of Lianyungang
Uterine Cervical Neoplasms
1 trial -
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
Teva Pharma GmbH
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1 trial -
Paclitaxel, Cisplatin Plus 5-FU (TCF)
The First People's Hospital of Lianyungang
Esophageal Cancer Stage IIB
1 trial -
Palazestrant
Olema Pharmaceuticals
Breast Cancer
3 trials -
Palazestrant matching placebo tablets and Letrozole matching placebo capsules, Palazestrant, RIBOCICLIB, Palazestrant, -, LETROZOLE , Palazestrant
Olema Pharmaceuticals
ER+, HER2- Advanced Breast Cancer
1 trial -
Palazestrant, FULVESTRANT, Palazestrant, EXEMESTANE, GOSERELIN , LETROZOLE, Palazestrant, Palazestrant, ANASTROZOLE
Olema Pharmaceuticals
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy
1 trial -
Palbociclib
Pfizer
Metastatic Breast Cancer
1 trial -
Palliative Chemotherapy
Sun Yat-sen University
Colorectal Neoplasms Malignant
1 trial -
Pamiparib capsule
BeiGene
Ovarian Cancer
1 trial -
Pamiparib capsule
BEONE MEDICINES AUS PTY LTD
Ovarian Cancer
1 trial -
Panitumumab
Amgen
Metastatic Colorectal Cancer
1 trial -
Pegylated Interferon Alfa-2a
Hoffmann-La Roche
Chronic Myelogenous Leukemia
1 trial -
Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung
Incyte
Cholangiocarcinoma
1 trial -
Pembrolizumab
Incyte
Renal Cell Carcinoma (RCC)
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Renal Cell Carcinoma
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Carcinoma, Renal Cell
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Ovarian Cancer
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Metastatic Esophageal Squamous Cell Carcinoma
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.
Data attribution: Data sources · All pipeline programs